News | May 11, 2026
Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Approval strengthens the company’s growing international anti-infective portfolio
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
